NCT02165332View on ClinicalTrials.gov

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Healthy Volunteer

Interventions

DRUG

Part 1: SAD RO7033877

Single dose

DRUG

Part 1: SAD placebo

Single dose

DRUG

Part 2: Treatment A, RO7033877

Single dose RO7033877 and moxifloxacin placebo

DRUG

Part 2: Treatment B, RO7033877

Single dose RO7033877 and moxifloxacin placebo

DRUG

Part 2: Treatment C, moxifloxacin

Single dose moxifloxacin and RO7033877 placebo

DRUG

Part 2: Treatment D, RO7033877 and moxifloxacin placebo

Single dose moxifloxacin placebo and RO7033877 placebo

Trial Locations (1)

66219

Lenexa

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT02165332 - A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval | Biotech Hunter | Biotech Hunter